Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.
Kawai M, Takada M, Nakayama T, Masuda N, Shiheido H, Cai Z, Huang YJ, Kawaguchi T, Tanizawa Y. Kawai M, et al. Among authors: tanizawa y. Breast Cancer Res Treat. 2023 Jan;197(2):435-447. doi: 10.1007/s10549-022-06816-9. Epub 2022 Nov 21. Breast Cancer Res Treat. 2023. PMID: 36414795 Free PMC article.
Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
Shinozaki E, Makiyama A, Kagawa Y, Satake H, Tanizawa Y, Cai Z, Piao Y. Shinozaki E, et al. Among authors: tanizawa y. PLoS One. 2021 Feb 8;16(2):e0246160. doi: 10.1371/journal.pone.0246160. eCollection 2021. PLoS One. 2021. PMID: 33556095 Free PMC article.
Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database.
Hiraoka A, Tanizawa Y, Huang YJ, Cai Z, Sakaguchi S. Hiraoka A, et al. Among authors: tanizawa y. Drugs Real World Outcomes. 2021 Sep;8(3):301-314. doi: 10.1007/s40801-021-00245-8. Epub 2021 Apr 1. Drugs Real World Outcomes. 2021. PMID: 33792850 Free PMC article.
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt JS, Mori J, Sakaguchi S, Kawaguchi T, Tanizawa Y, Llombart-Cussac A, Sledge GW Jr, Toi M. Inoue K, et al. Among authors: tanizawa y. Breast Cancer. 2021 Sep;28(5):1038-1050. doi: 10.1007/s12282-021-01239-8. Epub 2021 Apr 1. Breast Cancer. 2021. PMID: 33797023 Free PMC article. Clinical Trial.
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Takahashi M, et al. Among authors: tanizawa y. Breast Cancer. 2022 Jan;29(1):174-184. doi: 10.1007/s12282-021-01295-0. Epub 2021 Oct 18. Breast Cancer. 2022. PMID: 34661821 Free PMC article. Clinical Trial.
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.
Satake H, Kagawa Y, Shinozaki E, Tanizawa Y, Jin L, Cai Z, Makiyama A. Satake H, et al. Among authors: tanizawa y. Adv Ther. 2022 Jun;39(6):2596-2613. doi: 10.1007/s12325-022-02122-4. Epub 2022 Apr 6. Adv Ther. 2022. PMID: 35384550 Free PMC article.
396 results